April 30, 2026

What Is the Optimal Setting for T-DXd in Early Breast Cancer? Experts Differ

Trastuzumab deruxtecan (T-DXd) has claimed a large share of the HER2-positive breast cancer landscape, even finding room among tumors previously thought to be HER2-negative. The DESTINY series of tria...

The ASCO Post

April 28, 2026

Neoadjuvant Durvalumab and Chemotherapy in Triple-Negative Breast Cancer: Long-Term Follow-Up of GeparNuevo Trial

As reported in the Journal of Clinical Oncology by Loibl et al, long-term analysis of the German phase II GeparNuevo trial showed continued benefit in outcomes with neoadjuvant durvalumab vs placebo f...

The ASCO Post

April 17, 2026

Dana-Farber Researchers Presented More Than 50 Research Studies at American Association for Cancer Research Annual Meeting 2026

Select presentations by Dana-Farber faculty include a promising clinical trial chemotherapy and RAS inhibitor combination for pancreatic patients, new research on mapping the tumor microbiome using the presence of microorganisms and encouraging results from a clinical trial for older patients with multiple myeloma precursor conditions.

Dana-Farber

April 15, 2026

Is Standard of Care Optimal for the Individual Patient?

I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded ...

The ASCO Post

April 09, 2026

Japanese Study Looks at Rates of Cancer Therapy–Related AML

A population-based study in Japan has revealed a gradual increase in the rates of therapy-related acute myeloid leukemia (AML) in recent years—especially after breast cancer treatment. 

The ASCO Post

April 08, 2026

Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis

Results from a small phase II study suggest that a triplet regimen may improve symptoms and extend survival in some patients with breast cancer and leptomeningeal metastasis, who often face limited tr...

The ASCO Post

April 03, 2026

HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patien...

The ASCO Post

January 29, 2026

Addition of CDK 4/6 inhibitor benefits patients with HR+, HER2+ metastatic breast cancer, new study shows

The addition of a CDK 4/6 inhibitor to standard therapy in patients with “double-positive” metastatic breast cancer significantly extended the time the disease did not progress according to data published today in the New England Journal of Medicine.

Dana-Farber

April 01, 2026

Early Results From a Trial of Active Surveillance for Low-Risk DCIS are ‘Reassuring,’ Say Researchers

“For women with low-risk DCIS, these interim results are reassuring. There is currently no indication that active surveillance leads to worse early outcomes compared with immediate surgery. It’s impor...

The ASCO Post

March 10, 2023

Four Leading UPMC/Pitt Scientists Receive Funding for Research in Breast Cancer

UMPC Hillman Cancer Center researchers receive significant funding from the Breast Cancer Research Foundation to support investigations aiming to improve cancer screening and enhance HER2 therapy.

The ASCO Post